Author

Ada D’Addosio

Observed names: Ada D'Addosio, Ada M D'Addosio, Ada M D’Addosio, Ada M. D'Addosio, Ada M. D’Addosio

Observed institutions: Università Cattolica del Sacro Cuore, University of Rome Tor Vergata, Azienda Ospedaliera San Giovanni Addolorata, Fatebenefratelli Hospital, Ospedale San Pietro Fatebenefratelli, Sapienza University of Rome

OpenAlex ID: A5112227728

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

2013 · Maria Teresa Voso, Susanna Fenu, et al. · Journal of Clinical Oncology · 135

Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study

2013 · Roberto Latagliata, Dario Ferrero, et al. · Drugs & Aging · 42

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

2014 · Massimo Breccia, Luigiana Luciano, et al. · Leukemia Research · 35

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

2016 · Alessandra Iurlo, Alessandro Nobili, et al. · Oncotarget · 34

PDF

Deferasirox chelation therapy in patients with transfusion‐dependent MDS : a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata

2015 · Luca Maurillo, Massimo Breccia, et al. · European Journal Of Haematology · 24

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

2018 · Ambra Di Veroli, Alessia Campagna, et al. · Leukemia Research · 9

Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN

2016 · Ambra Di Veroli, Marianna De Muro, et al. · Blood · 4

Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?

2011 · Roberto Latagliata, Massimo Breccia, et al. · Blood · 3

Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival

2011 · Massimo Breccia, Luigiana Luciano, et al. · Blood · 2

Treatment with Imatinib in Very Elderly (> 75 Years) CML Patients.

2008 · Roberto Latagli Ata, Massimo Breccia, et al. · Blood · 2

Gastrointestinal cancer in patients with chronic myeloid leukemia on busulphan treatment

1990 · Sergio Storti, Livio Pagano, et al. · American Journal of Hematology · 2

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

2022 · Roberto Latagliata, Alessandro Andriani, et al. · Blood · 1

Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN)

2016 · Raffaele Porrini, Alessia Campagna, et al. · Blood · 1

Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment

2011 · Dario Ferrero, Roberto Latagliata, et al. · Blood · 1

Imatinib In Very Elderly CML Patients: What Can We Achieve?.

2010 · Roberto Latagliata, Dario Ferrero, et al. · Blood · 1

Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

2022 · Alessandro Andriani, Massimo Breccia, et al. · Blood

Incidence of Early Adverse Events in Primary Myelofibrosis (PMI). a Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN

2017 · Ambra Di Veroli, Elena Rossi, et al. · Blood

Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN

2016 · Marianna De Muro, Ambra Di Veroli, et al. · Blood

Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response

2015 · Alessandra Iurlo, Roberto Latagliata, et al. · Blood

Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline

2015 · Roberto Latagliata, Massimo Breccia, et al. · Blood

Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?

2011 · Roberto Latagliata, Massimo Breccia, et al. · Institutional Research Information System University of Turin (University of Turin)

Works count: 21

Citation count: 296

H-index: 6

I10-index: 5